These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9836606)

  • 1. Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
    Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
    J Med Chem; 1998 Dec; 41(25):4911-4. PubMed ID: 9836606
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans.
    Ananthan S; Kezar HS; Saini SK; Khare NK; Davis P; Dersch CM; Porreca F; Rothman RB
    Bioorg Med Chem Lett; 2003 Feb; 13(3):529-32. PubMed ID: 12565965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of BU09059: a novel potent selective κ-receptor antagonist.
    Casal-Dominguez JJ; Furkert D; Ostovar M; Teintang L; Clark MJ; Traynor JR; Husbands SM; Bailey SJ
    ACS Chem Neurosci; 2014 Mar; 5(3):177-84. PubMed ID: 24410326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists.
    Larson DL; Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
    J Med Chem; 2000 Apr; 43(8):1573-6. PubMed ID: 10780914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of 7-arylmorphinans. Probing the "address" requirements for selectivity at opioid delta receptors.
    Gao P; Larson DL; Portoghese PS
    J Med Chem; 1998 Jul; 41(16):3091-8. PubMed ID: 9685249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diprenorphine has agonist activity at opioid kappa-receptors in the myenteric plexus of the guinea-pig ileum.
    Traynor JR; Corbett AD; Kosterlitz HW
    Eur J Pharmacol; 1987 May; 137(1):85-9. PubMed ID: 3038579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selectivity of the opioid antagonist, naltrindole, for delta-opioid receptors.
    Rogers H; Hayes AG; Birch PJ; Traynor JR; Lawrence AJ
    J Pharm Pharmacol; 1990 May; 42(5):358-9. PubMed ID: 1976787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
    Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
    J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
    Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
    Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (-)-N,N'-but-2-ene-1,4-diylbimorphinans.
    Schmidhammer H; Smith CF; Dalkner E; Erlach D; Heuberger M; Rollinger JM
    Pharmazie; 1991 Feb; 46(2):101-2. PubMed ID: 1649476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
    Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
    Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporter affinity labels: an o-phthalaldehyde derivative of beta-naltrexamine as a fluorogenic ligand for opioid receptors.
    Le Bourdonnec B; El Kouhen R; Lunzer MM; Law PY; Loh HH; Portoghese PS
    J Med Chem; 2000 Jun; 43(13):2489-92. PubMed ID: 10891107
    [No Abstract]   [Full Text] [Related]  

  • 14. delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole.
    Coop A; Rothman RB; Dersch C; Partilla J; Porreca F; Davis P; Jacobson AE; Rice KC
    J Med Chem; 1999 May; 42(9):1673-9. PubMed ID: 10229636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist.
    Portoghese PS; Sultana M; Takemori AE
    Eur J Pharmacol; 1988 Jan; 146(1):185-6. PubMed ID: 2832195
    [No Abstract]   [Full Text] [Related]  

  • 16. Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues.
    James MK; Feldman PL; Schuster SV; Bilotta JM; Brackeen MF; Leighton HJ
    J Pharmacol Exp Ther; 1991 Nov; 259(2):712-8. PubMed ID: 1658308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
    Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
    J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transporters.
    Munro TA; Huang XP; Inglese C; Perrone MG; Van't Veer A; Carroll FI; Béguin C; Carlezon WA; Colabufo NA; Cohen BM; Roth BL
    PLoS One; 2013; 8(8):e70701. PubMed ID: 23976952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 14-Desoxy analogues of naltrindole and 7-spiroindanyloxymorphone: the role of the 14-hydroxy group at delta opioid receptors.
    Kshirsagar TA; Fang X; Portoghese PS
    J Med Chem; 1998 Jul; 41(14):2657-60. PubMed ID: 9651172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K303⁶·⁵⁸ in the μ opioid (MOP) receptor is important in conferring selectivity for covalent binding of β-funaltrexamine (β-FNA).
    DiMattio KM; Chen C; Shi L; Liu-Chen LY
    Eur J Pharmacol; 2015 Feb; 748():93-100. PubMed ID: 25481857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.